Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes:: Lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia

被引：0

|

作者：

Robertson, K

Schönle, E

Gucev, Z

Mordhorst, L

Tamer, SC

Gall, MA

Ludvigsson, J

机构：

来源：

DIABETES | 2004年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A144 / A144

页数：1

相关论文

共 50 条

[1] Benefits of insulin detemir over NPH insulin in children and adolescents with Type 1 diabetes:: Lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycaemia
Robertson, KJ
Schönle, E
Gucev, Z
Mordhorst, L
Tamer, SC
Gall, MA
Ludvigsson, J
[J]. DIABETOLOGIA, 2004, 47 : A32 - A32
[2] Insulin detemir is associated with more predictable glycemic control and lower risk of hypoglycemia compared to NPH insulin in subjects with type 1 diabetes
Vague, P
Selam, JL
Skeie, S
De Leeuw, I
Willem, J
Elte, F
Haahr, H
Kristensen, A
Draeger, E
[J]. DIABETES, 2002, 51 : A116 - A117
[3] Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with Type 1 diabetes
Russell-Jones, D
Bolinder, J
Simpson, R
[J]. DIABETOLOGIA, 2002, 45 : A51 - A51
[4] Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with Type 1 diabetes
Kolendorf, K
Prasek, M
Santeusanio, F
Philotheou, A
Gall, MA
Heller, S
[J]. DIABETOLOGIA, 2004, 47 : A329 - A329
[5] Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes
Kolendorf, K
Pavlic-Renar, I
San-Teusanio, F
Philotheou, A
Gall, MA
Heller, S
[J]. DIABETES, 2004, 53 : A130 - A131
[6] Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Robertson, K. J.
Schoenle, E.
Gucev, Z.
Mordhorst, L.
Gall, M. -A.
Ludvigsson, J.
[J]. DIABETIC MEDICINE, 2007, 24 (01) : 27 - 34
[7] Lower risk of nocturnal hypoglycemia with insulin detemir versus NPH insulin in people with diabetes: A meta-analysis of controlled phase III trials
Heller, S
Olsen, KJ
Draeger, E
[J]. DIABETES, 2004, 53 : A487 - A487
[8] Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes
Kolendorf, K.
Ross, G. P.
Pavlic-Renar, I.
Perriello, G.
Philotheou, A.
Jendle, J.
Gall, M-A.
Heller, S. R.
[J]. DIABETIC MEDICINE, 2006, 23 (07) : 729 - 735
[9] Insulin detemir achieves lower, less variable fasting glucose and a reduced risk of nocturnal hypoglycaemia and weight gain compared to NPH insulin in basal bolus therapy of Japanese patients with type 1 diabetes
Kobayashi, M.
Iwamoto, Y.
Kawamori, R.
Tajima, N.
Nishida, T.
Kaku, K.
[J]. DIABETOLOGIA, 2006, 49 : 608 - 609
[10] Lower severe hypoglycemia risk: Insulin glargine versus NPH insulin in type 2 diabetes
Dailey, George
Strange, Poul
[J]. AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (01): : 25 - 30

← 1 2 3 4 5 →